S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.72 (+0.64%)
GE   11.51 (+1.95%)
BAC   32.92 (+0.67%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.72 (+0.64%)
GE   11.51 (+1.95%)
BAC   32.92 (+0.67%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.72 (+0.64%)
GE   11.51 (+1.95%)
BAC   32.92 (+0.67%)
S&P 500   3,120.46 (+0.77%)
DOW   28,004.89 (+0.80%)
QQQ   202.72 (+0.64%)
GE   11.51 (+1.95%)
BAC   32.92 (+0.67%)
Log in

Recro Pharma Stock Price, Forecast & Analysis (NASDAQ:REPH)

$17.14
+0.63 (+3.82 %)
(As of 11/15/2019 04:00 PM ET)
Today's Range
$16.45
Now: $17.14
$17.36
50-Day Range
$10.82
MA: $13.16
$17.55
52-Week Range
$5.53
Now: $17.14
$18.20
Volume21,188 shs
Average Volume333,178 shs
Market Capitalization$389.59 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.4
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain. Read More…

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:REPH
CUSIPN/A
Phone484-395-2470

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$77.35 million
Book Value($0.87) per share

Profitability

Net Income$-79,720,000.00

Miscellaneous

Employees255
Market Cap$389.59 million
Next Earnings Date2/18/2020 (Estimated)
OptionableOptionable

Receive REPH News and Ratings via Email

Sign-up to receive the latest news and ratings for REPH and its competitors with MarketBeat's FREE daily newsletter.


Recro Pharma (NASDAQ:REPH) Frequently Asked Questions

What is Recro Pharma's stock symbol?

Recro Pharma trades on the NASDAQ under the ticker symbol "REPH."

How were Recro Pharma's earnings last quarter?

Recro Pharma Inc (NASDAQ:REPH) announced its earnings results on Friday, November, 8th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.13) by $0.06. The specialty pharmaceutical company had revenue of $25.26 million for the quarter, compared to the consensus estimate of $19.83 million. View Recro Pharma's Earnings History.

When is Recro Pharma's next earnings date?

Recro Pharma is scheduled to release their next quarterly earnings announcement on Tuesday, February 18th 2020. View Earnings Estimates for Recro Pharma.

What price target have analysts set for REPH?

4 brokerages have issued 12-month target prices for Recro Pharma's stock. Their forecasts range from $7.50 to $23.00. On average, they anticipate Recro Pharma's share price to reach $15.88 in the next twelve months. This suggests that the stock has a possible downside of 7.9%. View Analyst Price Targets for Recro Pharma.

What is the consensus analysts' recommendation for Recro Pharma?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Recro Pharma in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Recro Pharma.

Has Recro Pharma been receiving favorable news coverage?

News coverage about REPH stock has trended somewhat negative recently, InfoTrie reports. The research group scores the sentiment of news coverage by monitoring more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Recro Pharma earned a news sentiment score of -1.4 on InfoTrie's scale. They also assigned news stories about the specialty pharmaceutical company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near future. View News Stories for Recro Pharma.

Are investors shorting Recro Pharma?

Recro Pharma saw a increase in short interest in October. As of October 31st, there was short interest totalling 934,100 shares, an increase of 18.9% from the September 30th total of 785,900 shares. Based on an average daily volume of 215,900 shares, the days-to-cover ratio is currently 4.3 days. Approximately 4.8% of the shares of the company are sold short. View Recro Pharma's Current Options Chain.

Who are some of Recro Pharma's key competitors?

What other stocks do shareholders of Recro Pharma own?

Who are Recro Pharma's key executives?

Recro Pharma's management team includes the folowing people:
  • Dr. Geraldine A. Henwood, Pres, CEO & Director (Age 67)
  • Mr. Ryan D. Lake, Chief Financial Officer (Age 42)
  • Mr. Michael Celano, COO & Corp. Sec. (Age 60)
  • Mr. Randall J. Mack, Sr. VP of Devel. & Corp. Sec. (Age 54)
  • Ms. Diane Myers, Sr. VP of Regulatory Affairs & Quality Assurance (Age 55)

Who are Recro Pharma's major shareholders?

Recro Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Essex Investment Management Co. LLC (0.85%), Wedge Capital Management L L P NC (0.63%), Cadence Capital Management LLC (0.55%), Monarch Partners Asset Management LLC (0.39%), Chicago Equity Partners LLC (0.39%) and California Public Employees Retirement System (0.30%). Company insiders that own Recro Pharma stock include Arnaud Ajdler, Geraldine Henwood, Healthcare Master Fun Broadfin, Scp Vitalife Partners (Israel) and Scp Vitalife Partners Ii Lp. View Institutional Ownership Trends for Recro Pharma.

Which institutional investors are selling Recro Pharma stock?

REPH stock was sold by a variety of institutional investors in the last quarter, including Strs Ohio, Dupont Capital Management Corp, Wedge Capital Management L L P NC, Essex Investment Management Co. LLC, Cadence Capital Management LLC and Meeder Asset Management Inc.. View Insider Buying and Selling for Recro Pharma.

Which institutional investors are buying Recro Pharma stock?

REPH stock was acquired by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, Russell Investments Group Ltd., Chicago Equity Partners LLC, Monarch Partners Asset Management LLC, California Public Employees Retirement System, Tower Research Capital LLC TRC and Oppenheimer & Co. Inc.. View Insider Buying and Selling for Recro Pharma.

How do I buy shares of Recro Pharma?

Shares of REPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Recro Pharma's stock price today?

One share of REPH stock can currently be purchased for approximately $17.23.

How big of a company is Recro Pharma?

Recro Pharma has a market capitalization of $391.64 million and generates $77.35 million in revenue each year. The specialty pharmaceutical company earns $-79,720,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Recro Pharma employs 255 workers across the globe.View Additional Information About Recro Pharma.

What is Recro Pharma's official website?

The official website for Recro Pharma is http://www.recropharma.com/.

How can I contact Recro Pharma?

Recro Pharma's mailing address is 490 LAPP ROAD, MALVERN PA, 19355. The specialty pharmaceutical company can be reached via phone at 484-395-2470 or via email at [email protected]


MarketBeat Community Rating for Recro Pharma (NASDAQ REPH)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  309 (Thanks for Voting!)
Underperform Votes:  257 (Thanks for Voting!)
Total Votes:  566
MarketBeat's community ratings are surveys of what our community members think about Recro Pharma and other stocks. Vote "Outperform" if you believe REPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe REPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 11/15/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel